Genprex Announces Positive Preclinical Data for Reqorsa Gene Therapy

On October 28, 2025, Genprex, Inc. announced that its research collaborators presented positive preclinical data at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics. The data highlighted the efficacy of Genprex’s lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in treating ALK-EML4 positive non-small cell lung cancer (NSCLC). The study demonstrated that Reqorsa can overexpress the tumor suppressor gene TUSC2, inducing apoptosis in ALK+ NSCLC cells, including those resistant to alectinib. Combining Reqorsa with alectinib further increased apoptosis and improved survival in mouse models. These findings support the potential for a future clinical trial in ALK-positive lung cancer. The company believes these results open a pathway for further development and clinical testing of Reqorsa in combination with ALK inhibitors.